To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves BMS's Opdivo in HCC, sBLA gets Priority Review for expanded melanoma indication

In September, Bristol-Myers Squibb Co. (NYSE:BMY) said FDA granted accelerated approval to Opdivo nivolumab (BMS-936558, MDX-1106, ONO-4538) to treat hepatocellular carcinoma (HCC) in patients previously treated with Nexavar sorafenib.

Read the full 290 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE